Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Drugmaker Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce ...

Drugmaker Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce ...

The results bring Eli Lilly's pill orforglipron one step closer to becoming a new, needle-free alternative in the booming ...

Eli Lilly stock rises more than 11% as weight loss pill orforglipron shows promising trial results, raising hopes for a ...

AKT inhibitor Truqap (capivasertib) has been cleared by NICE for use in combination with standard therapy fulvestrant for ...

Rival companies trying to develop oral weight-loss candidates include Novo Nordisk, which has an oral formulation of ...

President Donald Trump has ordered the Department of Health and Human Services to standardize Medicare payments in an effort ...

Madrigal Pharmaceuticals has hired a former Novartis executive to succeed its retiring founder as chief medical officer.

Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid ...

In 2016, Ionis won approval for an infusion called Spinraza. After Zolgensma was approved, Roche won approval for a pill. Last year, Scholar Rock announced data for an antibody that targets ...